Key Points
- Ascendis Pharma SVP Mads Bodenhoff sold 3,000 shares at an average price of $270.19, generating $810,570 and reducing his ownership by 50%.
- ASND was down 3.4% and opened at $260.81, while its latest quarterly EPS of $1.03 missed estimates of $1.71 despite revenue of $387.22 million exceeding forecasts.
- Wall Street remains broadly bullish, with a consensus “Buy” rating and an average price target of $310.05; several institutional investors also recently increased their holdings.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) SVP Mads Bodenhoff sold 3,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company's stock, valued at $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Ascendis Pharma A/S Stock Down 3.4%
ASND opened at $260.81 on Thursday. The business has a 50 day moving average of $257.91 and a 200-day moving average of $241.71. The stock has a market capitalization of $16.27 billion, a price-to-earnings ratio of 20.23 and a beta of 0.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post 5.15 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on ASND. BMO Capital Markets reiterated an "outperform" rating on shares of Ascendis Pharma A/S in a research report on Thursday. Barclays dropped their price target on Ascendis Pharma A/S from $345.00 to $329.00 and set an "overweight" rating for the company in a report on Friday, August 14th. Wall Street Zen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Evercore restated an "outperform" rating and issued a $329.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Weiss Ratings raised Ascendis Pharma A/S from a "sell (d)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $310.05.
Read Our Latest Stock Analysis on ASND
Institutional Trading of Ascendis Pharma A/S
A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Wellington Management Group LLP raised its position in Ascendis Pharma A/S by 95.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company's stock worth $357,645,000 after purchasing an additional 880,836 shares during the last quarter. Perceptive Advisors LLC boosted its position in Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company's stock valued at $350,282,000 after buying an additional 450,000 shares during the last quarter. Vestal Point Capital LP boosted its position in Ascendis Pharma A/S by 200.0% in the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company's stock valued at $119,286,000 after buying an additional 400,000 shares during the last quarter. FIL Ltd increased its stake in shares of Ascendis Pharma A/S by 4.2% in the 4th quarter. FIL Ltd now owns 478,641 shares of the biotechnology company's stock valued at $102,065,000 after buying an additional 19,301 shares during the period. Finally, Adage Capital Partners GP L.L.C. increased its stake in shares of Ascendis Pharma A/S by 40.4% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 459,606 shares of the biotechnology company's stock valued at $79,328,000 after buying an additional 132,201 shares during the period.
Ascendis Pharma A/S Company Profile
(
Get Free Report)
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.
Ascendis' marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
